A Phase 2 interventional study of GRT6005 and Morphine in Post Operative Pain, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.
Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 113th largest by enrollment of the 1,098 interventional ones that give a count, is one of 26 that started in 2009, is one of 121 in phase 2, and was the 79th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
Columbia University · Sites in United States
Ages 12–21
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 18+ · Women only
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 155 · Phase 3 179 · Phase 4 359
First in 1996; this study’s year is marked. 26 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 76 across the 1,098 interventional studies, 130 across the 82 observational. Of the 784 that completed or were terminated, 474 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
199 of 1,180 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
97 of the studies in Pain, Postoperative with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060495Phase 3Rutgers, The State University of New JerseyRADA16 for Adult Tonsillectomy | 2026-12-01 |
| NCT07539623Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | 2026-12-22 |
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 1,180 studies in Pain, Postoperative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to determine whether the new centrally acting analgesic is effective in comparison to placebo and an active comparator (morphine).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1
Drug: GRT6005
Dose 2
Drug: GRT6005
Dose 3
Drug: GRT6005
Morphine
Drug: Morphine
Placebo
Drug: Placebo
Sum of pain intensity 2-10 hours after Investigational medicinal product intake. Pain assessments
Time frame: 8 hours
Amount of rescue medication
Time frame: 24 hours
Adverse events
Adverse Events reported by the participant as well as electrocardiogram, a measure of electrical activity of the heart and laboratory values
Time frame: 24 hours
Time to first rescue medication
Time frame: 24 hours
Patient Global Impression of Change
Time frame: 24 hours
The record gives a start of Mar 2009, a primary completion of Aug 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol